Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis allows generic sales in return for royalties

French drug maker sanofi-aventis has agreed to allow the sale of generic versions of some of its allergy drugs in return for royalties

French drug maker sanofi-aventis has agreed to allow the sale of generic versions of some of its allergy drugs in return for royalties.

The agreement settles a three-year US patent infringement suit issued against generic manufacturers Barr Pharmaceuticals and Teva Pharmaceuticals. The agreement states that in exchange for royalties, Barr and Teva can sell cheaper versions of the allergy drugs Allegra and Nasacort in the US. Royalties are to be applied to sales retrospectively.

Under the terms of the agreement, Barr will have an option to purchase the finished pharmaceutical product from sanofi-aventis on a non-exclusive basis.

Sanofi-aventis is continuing with ongoing patent infringements suits against other generic manufacturers.

In 2007, US sales of Allegra and Nasacort totalled $276m and $301m, respectively.

19th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics